Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Abstract Background Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), has been shown to increase the efficacy of endocrine therapies in hormone receptor (HR)-positive metastatic breast cancer. However, because breast cancer is a highly heterogeneous disease, the responses of differen...
Main Authors: | Zongbi Yi, Fei Ma, Binliang Liu, Xiuwen Guan, Lixi Li, Chunxiao Li, Haili Qian, Binghe Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-5668-3 |
Similar Items
-
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane
by: Dinja T. Kruger, et al.
Published: (2020-03-01) -
Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
by: Zongbi Yi, et al.
Published: (2020-08-01) -
Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
by: Xiuwen Guan, et al.
Published: (2020-02-01) -
Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer
by: Berna Öksüzoğlu, et al.
Published: (2020-06-01) -
Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
by: Kelvin Teck-Hong Kuik, et al.
Published: (2014-10-01)